Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial

Abstract

BackgroundFlaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients.Methodology/Principal FindingsThis was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10±0.65 % vs. 0.09±0.52 %, P = 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2±18.1 vs. 1.2±2.4 µg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations.Conclusions/SignificanceDaily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes.Trial RegistrationClinicalTrials.gov NCT00363233

Oilseeds ameliorate metabolic parameters in male mice, while contained lignans inhibit 3T3-L1 adipocyte differentiation in vitro

“…The present work is based on recent epidemiological and experimental evidences, suggesting that lignan-rich foods, such as oilseeds, may improve metabolic functions underlying metabolic syndrome (MetS) [17,22,29,[32][33][34]. The focus was directed to study two of the most lignan-rich food sources: sesame and flaxseeds, which contain up to 1 % lignans (500-1,000 mg/100 g) [35,36].…”

No evidence of hypoglycemia or hypotension in older adults during 6 months of flax lignan supplementation in a randomized controlled trial: A safety evaluation

“…In the literature, the uncertainly concerning the health benefits of flaxseed lignans stems from the indeterminate amount of lignan administered in clinical trials when flaxseed products such as whole flaxseed or defatted flaxseed meal are used as the lignan source (Bloedon et al, 2008;Cornish et al, 2009;Demark-Wahnefried et al, 2008;Hallund et al 2008;Lucas et al, 2002;Pan et al, 2007;Zhang et al, 2008). Recently, standardized flaxseed products have become available for commercial sale and use.…”

Flaxseed Oil and Diabetes: A Systemic Review

“…In 2007 "Public Library of Science One" found that type 2 diabetics who consumed flax seed-derived lignin supplements for 12 weeks had lower average blood sugar levels as determined by the A1C test, a measurement of blood glucose control based on the percentage of hemoglobin in the blood that contains glucose molecules. A low score on the Hb A1C test indicates good blood glucose control over the past two to three months, while a high score indicates poor blood glucose control (Pan et al, 2007).…”